Autolus Therapeutics (NASDAQ:AUTL) Shares Up 5% - Still a Buy?

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report)'s share price traded up 5% during trading on Tuesday . The company traded as high as $2.33 and last traded at $2.32. 204,897 shares were traded during trading, a decline of 86% from the average session volume of 1,488,127 shares. The stock had previously closed at $2.21.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Redburn Atlantic upgraded shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price target on the stock in a report on Friday, November 15th. The Goldman Sachs Group raised shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and raised their target price for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $10.00 price target on shares of Autolus Therapeutics in a report on Thursday, December 5th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $10.40.

Autolus Therapeutics Trading Up 6.3 %

The firm has a market cap of $625.32 million, a PE ratio of -1.94 and a beta of 1.98. The company has a 50-day simple moving average of $3.10 and a 200 day simple moving average of $3.67.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same quarter in the prior year, the business posted ($0.26) EPS. On average, equities analysts expect that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Institutional Trading of Autolus Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP increased its stake in shares of Autolus Therapeutics by 35.4% during the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company's stock worth $87,919,000 after purchasing an additional 6,330,392 shares in the last quarter. FMR LLC increased its stake in Autolus Therapeutics by 44.6% during the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company's stock worth $64,519,000 after buying an additional 5,478,706 shares in the last quarter. Erste Asset Management GmbH acquired a new position in shares of Autolus Therapeutics during the third quarter valued at approximately $708,000. Renaissance Technologies LLC raised its holdings in shares of Autolus Therapeutics by 253.5% during the second quarter. Renaissance Technologies LLC now owns 1,145,056 shares of the company's stock valued at $3,985,000 after acquiring an additional 821,156 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new position in shares of Autolus Therapeutics in the third quarter valued at approximately $1,082,000. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.